Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0001210

Tobramycin for identification

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Tobramycin, Nebramycin Factor 6, O-[3-Amino-3-deoxy-α-D-glucopyranosyl-(1→6)]-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribohexopyranosyl-(1→4)]-2-deoxy-D-streptamine

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C18H37N5O9
Número de CAS:
32986-56-4
Peso molecular:
467.51
Beilstein:
1357507
Número MDL:
MFCD00077885
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329831309
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

tobramycin

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O

InChI

1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1

Clave InChI

NLVFBUXFDBBNBW-SNGYORCQSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Tobramycin for identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

Tobramycin is an aminoglycoside.
Mode of Action: Binds to 70S ribosomal subunit; inhibits translocation; elicits miscoding.
Spectrum of Activity: Gram negative bacteria. Not effective against Enterococci.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Pictogramas

Health hazard
GHS08

Palabra de señalización

Warning

Frases de peligro

H361f

Clasificaciones de peligro

Repr. 2

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
The Medical letter on drugs and therapeutics, 55(1419), 51-52 (2013-06-26)
Kate McKeage
Drugs, 73(16), 1815-1827 (2013-11-07)
Inhaled tobramycin, an aminoglycoside antibacterial, has been in widespread use in the form of a nebulized solution against Pseudomonas aeruginosa for many years. More recently, tobramycin inhalation powder (TIP; TOBI(®) Podhaler(™)) was formulated using PulmoSphere(™) technology for administration as a
David E Geller et al.
Journal of aerosol medicine and pulmonary drug delivery, 24(4), 175-182 (2011-03-15)
Abstract At present, the only approved inhaled antipseudomonal antibiotics for chronic pulmonary infections in patients with cystic fibrosis (CF) are nebulized solutions. However, prolonged administration and cleaning times, high administration frequency, and cumbersome delivery technologies with nebulizers add to the
C L Bonsignore
Pediatric nursing, 24(3), 258-259 (1999-02-13)
Inhaled tobramycin was recently approved by the FDA in a 300 mg formulation for inhalation. The new product, manufactured by PathoGenesis Corporation, is referred to as TOBI and is indicated for cystic fibrosis patients with Pseudomonas aeruginosa. The advantage of
Susan M Cheer et al.
Drugs, 63(22), 2501-2520 (2003-11-12)
Specifically formulated for nebulisation using the PARI LC PLUS reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients with cystic fibrosis
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico